Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 10, 2020
Daily News
June 10, 2020
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- NIID Aims to Start Preclinical Trials for Coronavirus Vaccines in Autumn: Flu Center Director
June 10, 2020
- Sanofi Rolls Out Soliqua Injection SoloStar for Type 2 Diabetes in Japan
June 10, 2020
- Xofluza Shows Favorable Results in Patients at High Risk of Flu Complications in Global PIII: Shionogi
June 10, 2020
- Japan Ethical Drug Sales Up 2.6% in April: Crecon
June 10, 2020
- Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
June 10, 2020
- Jiangsu Hengrui to Return Telomelysin’s China Rights to Oncolys
June 10, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…